Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	4	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	5	MAR 02	GBFULL: New full-text patent database on STN
NEWS	6	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	9	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	10	MAR 22	PATDPASPC - New patent database available
NEWS	11	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	12	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	13	APR 04	EMBASE - Database reloaded and enhanced
NEWS	14	APR 18	New CAS Information Use Policies available online
NEWS	15	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAplus and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	16	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAplus
NEWS	17	MAY 23	GBFULL enhanced with patent drawing images
NEWS	18	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	19	JUN 06	STN Patent Forums to be held in June 2005
NEWS	20	JUN 06	The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
NEWS	21	JUN 13	RUSSIAPAT: New full-text patent database on STN
NEWS	22	JUN 13	FRFULL enhanced with patent drawing images
NEWS	23	JUN 20	MEDICONF to be removed from STN
NEWS	24	JUN 27	MARPAT displays enhanced with expanded G-group definitions and text labels
NEWS	25	JUL 01	MEDICONF removed from STN
NEWS	26	JUL 07	STN Patent Forums to be held in July 2005

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items

NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:24:43 ON 10 JUL 2005

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:24:57 ON 10 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 JUL 2005 HIGHEST RN 854301-22-7
DICTIONARY FILE UPDATES: 8 JUL 2005 HIGHEST RN 854301-22-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
****

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10626299.str



chain nodes :
13 14 15 16 17 18 21 22 23 25
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
1-13 3-22 6-23 9-21 12-14 13-14 13-15 15-16 16-17 17-18 17-25
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
1-13 13-14 13-15 17-18 17-25
exact bonds :
3-22 6-23 9-21 12-14 15-16 16-17
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
21:CLASS 22:CLASS 23:CLASS 25:CLASS

L1 STRUCTURE UPLOADED

```
=> d l1
L1 HAS NO ANSWERS
L1                STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 10:25:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     59 TO ITERATE

100.0% PROCESSED       59 ITERATIONS                          1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          720 TO     1640
PROJECTED ANSWERS:               1 TO       80

L2             1 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 10:25:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   1358 TO ITERATE

100.0% PROCESSED     1358 ITERATIONS                         30 ANSWERS
SEARCH TIME: 00.00.01

L3            30 SEA SSS FUL L1

=> FIL CAPLUS
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                              ENTRY    SESSION
```

FULL ESTIMATED COST 161.33 161.54

FILE 'CAPLUS' ENTERED AT 10:25:26 ON 10 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 10 Jul 2005 VOL 143 ISS 3
FILE LAST UPDATED: 8 Jul 2005 (20050708/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 1 L3

=> d l4 ibib abs hitstr tot

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:414644 CAPLUS
DOCUMENT NUMBER: 140:423476
TITLE: Preparation of antiamyloid N-alkanol derivatives of phenylsulfonamides as inhibitors of β-amyloid peptide (β-AP) production
INVENTOR(S): Smith, David W.; Parker, Michael F.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 15 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004097572	A1	20040520	US 2003-626299	20030724
PRIORITY APPLN. INFO.:			US 2002-400241P P	20020801

OTHER SOURCE(S): MARPAT 140:423476
GI



I



II

AB The title compds. [I; X, Y = halo, hydroxymethyl, acetoxymethyl; R1 = alkyl, cycloalkyl, etc.; R2 = H, alkylcarbonyl, cycloalkylcarbonyl, etc.; R3 = H, alkyl; m = 1-6] which are inhibitors of β-amyloid peptide (β-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions characterized by aberrant extracellular deposition of amyloid, were prepared Thus, reacting allylmagnesium bromide with 4-chloro-N-(2,5-dichlorophenyl)-N-(1R)(1-methyl-2-oxoethyl)benzenesulfonamide afforded two isomers of II. The compds. I showed IC50 of <5 μM in the assay for inhibition of β-amyloid peptide. The pharmaceutical compns. and methods of treatment are also disclosed.

IT **691907-17-2P 691907-18-3P 691907-19-4P**
691907-20-7P 691907-22-9P 691907-23-0P
691907-24-1P 691907-26-3P 691907-28-5P
691907-30-9P 691907-58-1P 691907-70-7P
691907-77-4P 691907-85-4P 691907-92-3P
691907-99-0P 691908-05-1P 691908-10-8P
691908-17-5P 691908-24-4P 691908-31-3P
691908-43-7P 691908-49-3P 691908-68-6P
691908-76-6P 691908-83-5P 691909-34-9P
691909-41-8P 691909-47-4P 691909-53-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of antiamyloid N-(hydroxyalkyl) benzenzesulfonamides as inhibitors of β-amyloid peptide (β-AP) production)

RN 691907-17-2 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R,2S)-2-hydroxy-1-methyl-4-pentenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-18-3 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R,2R)-2-hydroxy-1-methyl-4-pentenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-19-4 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R)-2-hydroxy-1-methylpentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-20-7 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R)-3-hydroxy-1-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-22-9 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R,2S)-2-hydroxy-1-methylpentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-23-0 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R,2R)-2-hydroxy-1-methylpentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-24-1 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R,2S)-2-hydroxy-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-26-3 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R,2R)-2-hydroxy-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-28-5 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R)-2-hydroxy-1,3-dimethylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-30-9 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R)-2-hydroxy-1,4-dimethylpentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-58-1 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R)-2-hydroxy-1-methyl-4-pentynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-70-7 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R,2S)-2-hydroxy-1-methyl-4-phenylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-77-4 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R,2R)-2-hydroxy-1-methyl-4-phenylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-85-4 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R,2S)-2-hydroxy-1-methyl-5-hexenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-92-3 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R,2R)-2-hydroxy-1-methyl-5-hexenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-99-0 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(5-chloro-2-fluorophenyl)-N-[(1R,2S)-2-hydroxy-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691908-05-1 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(5-chloro-2-fluorophenyl)-N-[(1R,2R)-2-hydroxy-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691908-10-8 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(5-chloro-2-fluorophenyl)-N-[(1R,2S)-2-hydroxy-1-methyl-5-hexenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691908-17-5 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-(5-chloro-2-fluorophenyl)-N-[(1R,2R)-2-hydroxy-1-methyl-5-hexenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691908-24-4 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(5-chloro-2-fluorophenyl)-N-[(1R,2S)-2-hydroxy-1-methyl-4-pentynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691908-31-3 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(5-chloro-2-fluorophenyl)-N-[(1R,2R)-2-hydroxy-1-methyl-4-pentynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691908-43-7 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(5-chloro-2-fluorophenyl)-N-[(1R)-2-hydroxy-1-methyl-4-pentenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691908-49-3 CAPLUS
CN D-glycero-Pentonic acid, 4-[(5-chloro-2-fluorophenyl)[(4-chlorophenyl)sulfonyl]amino]-2,4,5-trideoxy-, (3ξ)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691908-68-6 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(5-chloro-2-fluorophenyl)-N-[(1R)-2-hydroxy-1-methylpentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691908-76-6 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R)-3-hydroxy-1,5-dimethylhexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691908-83-5 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R)-3-hydroxy-1-methyl-6-heptenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691909-34-9 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-(4-hydroxy-5-hexynyl)- (9CI) (CA INDEX NAME)



RN 691909-41-8 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(5-chloro-2-fluorophenyl)-N-(4-hydroxy-5-hexynyl)- (9CI) (CA INDEX NAME)



RN 691909-47-4 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(5-chloro-2-fluorophenyl)-N-(4-hydroxy-5-hexenyl)- (9CI) (CA INDEX NAME)



RN 691909-53-2 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(5-chloro-2-fluorophenyl)-N-(2-hydroxy-1-methylpentyl)- (9CI) (CA INDEX NAME)



=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.84	167.38

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.73	-0.73

FILE 'REGISTRY' ENTERED AT 10:26:23 ON 10 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 JUL 2005 HIGHEST RN 854301-22-7
DICTIONARY FILE UPDATES: 8 JUL 2005 HIGHEST RN 854301-22-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when

conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************
```

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10626299a.str



chain nodes :
13 14 15 16 17 18 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
1-13 12-14 13-14 13-15 15-16 16-17 17-18 17-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
1-13 13-14 13-15 17-18 17-22
exact bonds :
12-14 15-16 16-17
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
22:CLASS

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l5
SAMPLE SEARCH INITIATED 10:26:47 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1485 TO ITERATE

100.0% PROCESSED 1485 ITERATIONS 27 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 27389 TO 32011
PROJECTED ANSWERS: 229 TO 851

L6 27 SEA SSS SAM L5

=> s l5 sss full
FULL SEARCH INITIATED 10:26:54 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 30040 TO ITERATE

100.0% PROCESSED 30040 ITERATIONS 496 ANSWERS
SEARCH TIME: 00.00.02

L7 496 SEA SSS FUL L5

=> FIL CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.33	328.71

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.73

FILE 'CAPLUS' ENTERED AT 10:27:01 ON 10 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 10 Jul 2005 VOL 143 ISS 3
FILE LAST UPDATED: 8 Jul 2005 (20050708/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l7
L8 62 L7

=> s l8 and amyloid peptide
21198 AMYLOID
1655 AMYLOIDS
21286 AMYLOID
(AMYLOID OR AMYLOIDS)
332451 PEPTIDE
243122 PEPTIDES
425666 PEPTIDE
(PEPTIDE OR PEPTIDES)
2611 AMYLOID PEPTIDE
(AMYLOID(W)PEPTIDE)
L9 1 L8 AND AMYLOID PEPTIDE

=> s l8 and thu
141 THU
2247189 THUS
2247315 THU
(THU OR THUS)
L10 24 L8 AND THU

```
=> s l10 and p/dt
       4746741 P/DT
L11          22 L10 AND P/DT

=> s l11 and us/pc
       1387681 US/PC
L12          17 L11 AND US/PC

=> s l12 and py<=2002
      22591660 PY<=2002
L13          16 L12 AND PY<=2002

=> s l12 and py<=2001
      21607261 PY<=2001
L14          16 L12 AND PY<=2001

=> d his

     (FILE 'HOME' ENTERED AT 10:24:43 ON 10 JUL 2005)

     FILE 'REGISTRY' ENTERED AT 10:24:57 ON 10 JUL 2005
L1                STRUCTURE UPLOADED
L2             1 S L1
L3            30 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 10:25:26 ON 10 JUL 2005
L4             1 S L3

     FILE 'REGISTRY' ENTERED AT 10:26:23 ON 10 JUL 2005
L5                STRUCTURE UPLOADED
L6            27 S L5
L7           496 S L5 SSS FULL

     FILE 'CAPLUS' ENTERED AT 10:27:01 ON 10 JUL 2005
L8            62 S L7
L9             1 S L8 AND AMYLOID PEPTIDE
L10           24 S L8 AND THU
L11           22 S L10 AND P/DT
L12           17 S L11 AND US/PC
L13           16 S L12 AND PY<=2002
L14           16 S L12 AND PY<=2001

=> d l9 ibib abs hitstr tot

L9   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         2004:414644  CAPLUS
DOCUMENT NUMBER:          140:423476
TITLE:                    Preparation of antiamyloid N-alkanol derivatives of
                          phenylsulfonamides as inhibitors of β-
                          amyloid peptide (β-AP)
                          production
INVENTOR(S):              Smith, David W.; Parker, Michael F.
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ., 15 pp.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004097572	A1	20040520	US 2003-626299		20030724
PRIORITY APPLN. INFO.:			US 2002-400241P	P	20020801
OTHER SOURCE(S):	MARPAT 140:423476				

GI



I



II

AB The title compds. [I; X, Y = halo, hydroxymethyl, acetoxymethyl; R1 = alkyl, cycloalkyl, etc.; R2 = H, alkylcarbonyl, cycloalkylcarbonyl, etc.; R3 = H, alkyl; m = 1-6] which are inhibitors of β- **amyloid peptide** (β-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions characterized by aberrant extracellular deposition of amyloid, were prepared Thus, reacting allylmagnesium bromide with 4-chloro-N-(2,5-dichlorophenyl)-N-(1R)(1-methyl-2-oxoethyl)benzenesulfonamide afforded two isomers of II. The compds. I showed IC50 of <5 μM in the assay for inhibition of β- **amyloid peptide.** The pharmaceutical compns. and methods of treatment are also disclosed.

IT **691907-17-2P 691907-18-3P 691907-19-4P**
691907-20-7P 691907-22-9P 691907-23-0P
691907-24-1P 691907-26-3P 691907-28-5P
691907-30-9P 691907-58-1P 691907-70-7P
691907-77-4P 691907-85-4P 691907-92-3P
691907-99-0P 691908-05-1P 691908-10-8P
691908-17-5P 691908-24-4P 691908-31-3P
691908-43-7P 691908-49-3P 691908-68-6P
691908-76-6P 691908-83-5P 691909-34-9P
691909-41-8P 691909-47-4P 691909-53-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of antiamyloid N-(hydroxyalkyl) benzenzesulfonamides as inhibitors of β- **amyloid peptide** (β-AP) production)

RN 691907-17-2 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R,2S)-2-hydroxy-1-methyl-4-pentenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-18-3 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R,2R)-2-hydroxy-1-methyl-4-pentenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-19-4 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R)-2-hydroxy-1-methylpentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-20-7 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R)-3-hydroxy-1-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-22-9 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R,2S)-2-hydroxy-1-methylpentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-23-0 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R,2R)-2-hydroxy-1-methylpentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-24-1 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R,2S)-2-hydroxy-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-26-3 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R,2R)-2-hydroxy-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-28-5 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R)-2-hydroxy-1,3-dimethylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-30-9 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R)-2-hydroxy-1,4-dimethylpentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-58-1 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R)-2-hydroxy-1-methyl-4-pentynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-70-7 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R,2S)-2-hydroxy-1-methyl-4-phenylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-77-4 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R,2R)-2-hydroxy-1-methyl-4-phenylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-85-4 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R,2S)-2-hydroxy-1-methyl-5-hexenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-92-3 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R,2R)-2-hydroxy-1-methyl-5-hexenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691907-99-0 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(5-chloro-2-fluorophenyl)-N-[(1R,2S)-2-hydroxy-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691908-05-1 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(5-chloro-2-fluorophenyl)-N-[(1R,2R)-2-hydroxy-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691908-10-8 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(5-chloro-2-fluorophenyl)-N-[(1R,2S)-2-hydroxy-1-methyl-5-hexenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691908-17-5 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-(5-chloro-2-fluorophenyl)-N-[(1R,2R)-2-hydroxy-1-methyl-5-hexenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691908-24-4 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(5-chloro-2-fluorophenyl)-N-[(1R,2S)-2-hydroxy-1-methyl-4-pentynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691908-31-3 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(5-chloro-2-fluorophenyl)-N-[(1R,2R)-2-hydroxy-1-methyl-4-pentynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691908-43-7 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(5-chloro-2-fluorophenyl)-N-[(1R)-2-hydroxy-1-methyl-4-pentenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691908-49-3 CAPLUS
CN D-glycero-Pentonic acid, 4-[(5-chloro-2-fluorophenyl)[(4-chlorophenyl)sulfonyl]amino]-2,4,5-trideoxy-, (3ξ)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691908-68-6 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(5-chloro-2-fluorophenyl)-N-[(1R)-2-hydroxy-1-methylpentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691908-76-6 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R)-3-hydroxy-1,5-dimethylhexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691908-83-5 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-[(1R)-3-hydroxy-1-methyl-6-heptenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691909-34-9 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(2,5-dichlorophenyl)-N-(4-hydroxy-5-hexynyl)- (9CI) (CA INDEX NAME)



RN 691909-41-8 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(5-chloro-2-fluorophenyl)-N-(4-hydroxy-5-hexynyl)- (9CI) (CA INDEX NAME)



RN 691909-47-4 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(5-chloro-2-fluorophenyl)-N-(4-hydroxy-5-hexenyl)- (9CI) (CA INDEX NAME)



RN 691909-53-2 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-(5-chloro-2-fluorophenyl)-N-(2-hydroxy-1-methylpentyl)- (9CI) (CA INDEX NAME)



=> d l14 ibib abs hitstr 1-10

L14 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:811551 CAPLUS
DOCUMENT NUMBER: 132:49985
TITLE: 7-alkyl and cycloalkyl substituted imidazotriazinones
INVENTOR(S): Niewoehner, Ulrich; Es-Sayed, Mazen; Haning, Helmut; Schenke, Thomas; Schmidt, Gunter; Schlemmer, Karl-Heinz; Bischoff, Erwin; Dembowsky, Klaus; Perzborn, Elisabeth
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 284 pp.
CODEN: GWXXBX
DOCUMENT TYPE: **Patent**
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19827640	A1	19991223	DE 1998-19827640	19980620 <--
CA 2335193	AA	19991229	CA 1999-2335193	19990611 <--
WO 9967244	A1	19991229	WO 1999-EP4032	19990611 <--

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,

JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9946080	A1	20000110	AU 1999-46080		19990611 <--
EP 1090003	A1	20010411	EP 1999-929181		19990611 <--
R: DE, ES, FR, GB, IT					
JP 2002518500	T2	20020625	JP 2000-555897		19990611
US 6476029	B1	20021105	US 2001-720051		20010323 <--
US 6838459	B1	20050104	US 2002-251939		20020920 <--
US 2005049250	A1	20050303	US 2004-850510		20040520 <--
PRIORITY APPLN. INFO.:			DE 1998-19827640	A	19980620
			WO 1999-EP4032	W	19990611
			US 2001-720051	A1	20010323
			US 2002-251939	A1	20020920

OTHER SOURCE(S): MARPAT 132:49985
GI



I



II

AB Imidazotriazinones I [R = (un)substituted aminosulfonylphenyl; R1 = alkyl; R2 = alkyl, cycloalkyl] were prepared for use as phosphodiesterase inhibitors (no data). **Thus**, DL-alanine was acylated with cyclopentanecarbonyl chloride, treated with EtO2CCOCl, N2H4, and 2-EtOC6H4C(:NH)NH2.HCl to give 2-(2-ethoxyphenyl)-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one which was chlorosulfonylated and amidated with N-methylpiperazine to give the sulfonamide II.

IT **252675-37-9P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminosulfonylphenylimidazotriazinones as phosphodiesterase inhibitors)

RN 252675-37-9 CAPLUS

CN Benzenesulfonamide, 4-ethoxy-3-[7-(1-ethylheptyl)-1,4-dihydro-5-methyl-4-oxoimidazo[5,1-f][1,2,4]triazin-2-yl]-N-(3-hydroxybutyl)-N-phenyl- (9CI) (CA INDEX NAME)



L14 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:325936 CAPLUS
DOCUMENT NUMBER: 130:352283
TITLE: Preparation of 2-phenylimidazotriazinones as phosphodiesterase inhibitors.
INVENTOR(S): Niewohner, Ulrich; Es-Sayed, Mazen; Haning, Helmut; Schenke, Thomas; Schlemmer, Karl-Heinz; Keldenich, Jorg; Bischoff, Erwin; Perzborn, Elisabeth; Dembowsky, Klaus; Serno, Peter; Nowakowski, Marc
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 329 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9924433	A1	19990520	WO 1998-EP6910	19981031 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19750085	A1	19990520	DE 1997-19750085	19971112 <--
DE 19812462	A1	19990930	DE 1998-19812462	19980323 <--
DE 19840289	A1	20000309	DE 1998-19840289	19980904 <--
CA 2309332	AA	19990520	CA 1998-2309332	19981031 <--
CA 2309332	C	20021203		
CA 2395558	AA	19990520	CA 1998-2395558	19981031 <--
AU 9915587	A1	19990531	AU 1999-15587	19981031 <--
AU 738675	B2	20010920		
TR 200001338	T2	20000821	TR 2000-200001338	19981031 <--
GB 2346877	A1	20000823	GB 2000-10974	19981031 <--
GB 2346877	B2	20011205		
BR 9812785	A	20001010	BR 1998-12785	19981031 <--
EP 1049695	A1	20001108	EP 1998-959821	19981031 <--
EP 1049695	B1	20020213		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO

EE 200000291	A	20010615	EE 2000-291	19981031 <--
NZ 504436	A	20010831	NZ 1998-504436	19981031 <--
JP 2001522851	T2	20011120	JP 2000-520443	19981031 <--
JP 3356428	B2	20021216		
EP 1174431	A2	20020123	EP 2001-123321	19981031
EP 1174431	A3	20020130		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

DE 19881732	C1	20020131	DE 1998-19881732	19981031
AT 213246	E	20020215	AT 1998-959821	19981031
PT 1049695	T	20020731	PT 1998-959821	19981031
ES 2172945	T3	20021001	ES 1998-959821	19981031
JP 2002348290	A2	20021204	JP 2002-130480	19981031
CN 1123573	B	20031008	CN 1998-811092	19981031
ES 2194567	A1	20031116	ES 2000-200050033	19981031
ES 2194567	B1	20050301		
CH 693954	A	20040514	CH 2000-932	19981031
IN 188419	A	20020921	IN 1998-DE3276	19981105
ZA 9810297	A	19990520	ZA 1998-10297	19981111 <--
TW 513431	B	20021211	TW 1998-87118724	19981111
LU 90561	A1	20001201	LU 2000-90561	20000405 <--
BG 104406	A	20010831	BG 2000-104406	20000505 <--
FI 2000001086	A	20000509	FI 2000-1086	20000509 <--
FI 113772	B1	20040615		
NO 2000002444	A	20000511	NO 2000-2444	20000511 <--
NO 314940	B1	20030616		
SE 2000001745	A	20000511	SE 2000-1745	20000511 <--
SE 522809	C2	20040309		
HR 2000000292	A1	20010430	HR 2000-292	20000511 <--
MX 200004634	A	20001110	MX 2000-4634	20000512 <--
US 6362178	B1	20020326	US 2000-554162	20000721 <--
HK 1031730	A1	20041015	HK 2001-102357	20010402
US 6566360	B1	20030520	US 2001-943530	20010830 <--
NO 2002001714	A	20000511	NO 2002-1714	20020411 <--
US 2004067945	A1	20040408	US 2003-365740	20030212 <--
US 6890922	B2	20050510		
US 2005070541	A1	20050331	US 2004-923544	20040820 <--

PRIORITY APPLN. INFO.:

DE 1997-19750085	A	19971112
DE 1998-19812462	A	19980323
DE 1998-19840289	A	19980904
CA 1998-2309332	A3	19981031
EP 1998-959821	A3	19981031
JP 2000-520443	A3	19981031
WO 1998-EP6910	W	19981031
NO 2000-2444	A	20000511
US 2000-554162	A1	20000721
US 2001-943530	A1	20010830
US 2003-365740	A1	20030212

OTHER SOURCE(S): MARPAT 130:352283

GI



I

AB Title compds. [I; R1 = H, alkyl; R2 = alkyl; R3, R4 = H, alkenyl, alkoxy, (substituted) (O-interrupted) alkyl, amino, adamantyl, cycloalkyl, etc.; NR3R4 = 5-7 membered (benzo-fused) (unsatd.) heterocyclyl, etc.; R5, R6 = H, alkyl, OH, alkoxy], were prepared as cGMP-metabolizing phosphodiesterases for treating cardiovascular and cerebrovascular diseases and/or diseases of the urogenital system, especially for treating erectile dysfunction. **Thus**, 4-ethoxy-3-(5,7-dimethyl-4-oxo-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)benzenesulfonyl chloride (preparation given) in CH2Cl2 was treated with DMAP and N-methylpiperazine at 0° followed by stirring overnight to give 34.5% 2-[2-ethoxy-5-(4-methylpiperazin-1-ylsulfonyl)phenyl]-5,7-dimethyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one. I inhibited phosphodiesterase V with IC50 = 1-10 nM.

IT **224786-82-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-phenylimidazotriazinones as phosphodiesterase inhibitors)

RN 224786-82-7 CAPLUS

CN Benzenesulfonamide, 3-(1,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxy-N-(3-hydroxybutyl)-N-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:175689 CAPLUS
DOCUMENT NUMBER: 130:223060
TITLE: Preparation of pentafluorobenzenesulfonamides for treating atherosclerosis and hypercholesterolemia
INVENTOR(S): Medina, Julio Cesar; Clark, David Louis; Flygare, John A.; Rosen, Terry J.; Shan, Bei
PATENT ASSIGNEE(S): Tularik Inc., USA

SOURCE: U.S., 28 pp., Cont.-in-part of U.S. Ser. No. 605,431, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5880151	A	19990309	US 1997-896827	19970718 <--
~~EP 1334719~~	A2	20030813	EP 2003-9125	19970222
EP 1334719	A3	20030924		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PT 896533	T	20040227	PT 1997-907843	19970222
ES 2205183	T3	20040501	ES 1997-907843	19970222
US 6121304	A	20000919	US 1999-227216	19990106 <--
US 6316484	B1	20011113	US 2000-633740	20000807 <--
US 2002143036	A1	20021003	US 2001-972743	20011005 <--

PRIORITY APPLN. INFO.:

US 1996-605431	B2	19960222
EP 1997-907843	A3	19970222
US 1997-896827	A1	19970718
US 1999-227216	A1	19990106
US 2000-633740	A1	20000807

OTHER SOURCE(S): MARPAT 130:223060
GI



I

AB The title compds. [I; Y = SO, SO2; Z = NR1R2 (wherein R1 = H, (un)substituted C1-10 alkyl, C3-6 alkenyl, C2-6 heteroalkyl; R2 = (un)substituted Ph)], useful as pharmacol. agents in the treatment of disease states, particularly atherosclerosis, pancreatitis, hypercholesterolemia, and hyperlipoproteinemia or as lead compds. for the development of such agents, were prepared **Thus**, reaction of N,N-dimethyl-1,4-phenyldiamine.2HCl with pentafluorophenylsulfonyl chloride in pyridine afforded 63% I [Y = SO2; Z = 4-(Me2N)C6H4NH] which showed ECmax of 0.5 μM for their ability to increase LDL receptor expression in Hep G2 cells.

IT **195534-06-6P 195534-07-7P 195534-08-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pentafluorobenzenesulfonamides for treating atherosclerosis and hypercholesterolemia)

RN 195534-06-6 CAPLUS

CN Benzenesulfonamide, N-(2,3-dihydroxypropyl)-2,3,4,5,6-pentafluoro-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 195534-07-7 CAPLUS
CN Benzenesulfonamide, N-(3,4-dihydroxybutyl)-2,3,4,5,6-pentafluoro-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 195534-08-8 CAPLUS
CN Benzenesulfonamide, N-(4,5-dihydroxypentyl)-2,3,4,5,6-pentafluoro-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:424220 CAPLUS
DOCUMENT NUMBER: 129:95327

TITLE: Preparation of sulfonamide and carboxamide derivatives as drugs
INVENTOR(S): Ohuchida, Shuichi; Nagao, Yuuki
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan; Ohuchida, Shuichi; Nagao, Yuuki
SOURCE: PCT Int. Appl., 305 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9827053	A1	19980625	WO 1997-JP4593	19971212 <--
W: AU, CA, CN, HU, JP, KR, MX, NO, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
TW 523506	B	20030311	TW 1997-86118583	19971210
CA 2274954	AA	19980625	CA 1997-2274954	19971212 <--
AU 9854115	A1	19980715	AU 1998-54115	19971212 <--
AU 733493	B2	20010517		
EP 947500	A1	19991006	EP 1997-947925	19971212 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1247529	A	20000315	CN 1997-181861	19971212 <--
JP 3426252	B2	20030714	JP 1998-527533	19971212
ZA 9711336	A	19980625	ZA 1997-11336	19971217 <--
KR 2000057576	A	20000925	KR 1999-705335	19990615 <--
NO 9902935	A	19990816	NO 1999-2935	19990616 <--
MX 9905770	A	20000228	MX 1999-5770	19990618 <--
US 6448290	B1	20020910	US 1999-331327	19990618 <--
US 2003060460	A1	20030327	US 2002-207078	20020730 <--
US 6790866	B2	20040914		

PRIORITY APPLN. INFO.:		
JP 1996-353818	A	19961218
JP 1997-305055	A	19971021
WO 1997-JP4593	W	19971212
US 1999-331327	A3	19990618

OTHER SOURCE(S): MARPAT 129:95327
GI For diagram(s), see printed CA Issue.
AB The title compds. (I; rings A and B represent each a carbocycle or a heterocycle; Z1 represents COR1, CH:CHCOR1, etc.; R1 represents OH, C1-4 alkoxy, etc.; Z2 represents H, alkyl, etc.; Z3 represents a single bond or alkylene; Z4 represents SO2 or CO; Z5 represents alkyl, Ph, a heterocycle, etc., R2 represents CONR8, O, S, etc.; R8 represents H, C1-4 alkyl; R3 represents H, alkyl, halo, CF3, etc.; R4 represents H, optionally substituted alkyl, etc.; n, t = 1-4) are prepared I bind to prostaglandin E2 (PGE2) receptors and exert an antagonism. I have the effects of inhibiting uterine muscle contraction, analgesia, inhibiting digestive tract movement, hypnosis, enlarging vesical capacity, contracting the uterine, promoting the digestive tract movement, suppressing the secretion of gastric hydrochloric acid, lowering blood pressure, or diuresis. **Thus**, compound (II; W = Me) was treated with aqueous NaOH and followed by aqueous HCl to give the title compound II (W = H), which showed Ki of 0.099 μM against PGE2 receptors.
IT **209687-33-2P 209687-34-3P 209687-35-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamide and carboxamide derivs. as drugs)
RN 209687-33-2 CAPLUS

CN Benzoic acid, 4-[[2-[(2-hydroxy-2-methylpropyl)(phenylsulfonyl)amino]-5-(trifluoromethyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 209687-34-3 CAPLUS
CN 2-Propenoic acid, 3-[4-[[2-[(2-hydroxy-2-methylpropyl)(phenylsulfonyl)amino]-5-(trifluoromethyl)phenoxy]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 209687-35-4 CAPLUS
CN Benzoic acid, 4-[[2-[(2-hydroxy-2-methylpropyl)(phenylsulfonyl)amino]-5-methylphenoxy]methyl]- (9CI) (CA INDEX NAME)



IT **209688-21-1P 209688-22-2P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of sulfonamide and carboxamide derivs. as drugs)

RN 209688-21-1 CAPLUS
CN Benzenesulfonamide, N-(2-hydroxy-2-methylpropyl)-N-[2-(methoxymethoxy)-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209688-22-2 CAPLUS
CN Benzenesulfonamide, N-(2-hydroxy-2-methylpropyl)-N-[2-hydroxy-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:289989 CAPLUS
DOCUMENT NUMBER: 124:317189
TITLE: Preparation of phenoxyethylaminopyridazines as thrombin inhibitors.
INVENTOR(S): von der Saal, Wolfgang; Heck, Reinhard; Kucznierz, Ralf; Leinert, Herbert; Stegmeier, Karlheinz
PATENT ASSIGNEE(S): Boehringer Mannheim Gmbh, Germany
SOURCE: Ger. Offen., 14 pp.
CODEN: GWXXBX
DOCUMENT TYPE: **Patent**
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4430757	A1	19960307	DE 1994-4430757	19940830 <--
CA 2198366	AA	19960307	CA 1995-2198366	19950826 <--
WO 9606832	A1	19960307	WO 1995-EP3383	19950826 <--

W: AU, BG, BR, BY, CA, CN, CZ, EE, FI, HU, JP, KR, KZ, MX, NO, NZ, PL, RO, RU, SI, SK, UA, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

AU 9534736	A1	19960322	AU 1995-34736		19950826 <--
EP 778829	A1	19970618	EP 1995-931212		19950826 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
JP 10504833	T2	19980512	JP 1995-508485		19950826 <--
US 5795892	A	19980818	US 1997-793445		19970228 <--
PRIORITY APPLN. INFO.:			DE 1994-4430757	A	19940830
			WO 1995-EP3383	W	19950826

OTHER SOURCE(S): MARPAT 124:317189

GI



I

AB Title compds. [I; R1 = R2SO2O, R2SO2NR3; R2 = cycloalkyl, (substituted) aryl, heteroaryl; R3 = H, (substituted) alkyl, alkoxyalkyl], were prepared as antithrombotics (no data). **Thus** N-[3-(2-aminoethoxy)-5-methylphenyl]benzenesulfonamide (preparation given) was heated with 3,4,5-trichloropyridazine and Et3N in THF to give a mixture of N-[3-[2-(3,5-dichoropyridazin-4-ylamino)ethoxy]-5-methylphenyl]benzenesulfonamide and the 2,3-dichloropyridazin-4-yl isomer. The mixture was hydrogenated in MeOH in the presence of Raney Ni to give 79% N-[3-methyl-5-[2-(pyridazin-4-ylamino)ethoxy]phenyl]benzenesulfonamide.

IT **176382-13-1P 176382-14-2P 176382-15-3P**
176382-16-4P 176382-17-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenoxyethylaminopyridazines as thrombin inhibitors)

RN 176382-13-1 CAPLUS

CN Benzenesulfonamide, N-(2,3-dihydroxypropyl)-2-methoxy-N-[3-methyl-5-[2-(4-pyridazinylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 176382-14-2 CAPLUS

CN Benzenesulfonamide, N-(2,3-dihydroxypropyl)-N-[3-methyl-5-[2-(4-pyridazinylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 176382-15-3 CAPLUS
CN Benzenesulfonamide, N-(2,3-dihydroxypropyl)-2-fluoro-N-[3-methyl-5-[2-(4-pyridazinylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 176382-16-4 CAPLUS
CN Benzenesulfonamide, N-(2,3-dihydroxypropyl)-4-fluoro-2-methyl-N-[3-methyl-5-[2-(4-pyridazinylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 176382-17-5 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, N-(2,3-dihydroxypropyl)-N-[3-methyl-5-[2-(4-pyridazinylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



IT **176382-36-8P 176382-37-9P 176382-38-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenoxyethylaminopyridazines as thrombin inhibitors)
RN 176382-36-8 CAPLUS
CN Benzenesulfonamide, N-[3-(2-aminoethoxy)-5-methylphenyl]-N-(2,3-dihydroxypropyl)-2-methoxy- (9CI) (CA INDEX NAME)



RN 176382-37-9 CAPLUS
CN Benzenesulfonamide, N-[3-[2-[(3,5-dichloro-4-pyridazinyl)amino]ethoxy]-5-methylphenyl]-N-(2,3-dihydroxypropyl)-2-methoxy- (9CI) (CA INDEX NAME)



RN 176382-38-0 CAPLUS
CN Benzenesulfonamide, N-[3-[2-[(5,6-dichloro-4-pyridazinyl)amino]ethoxy]-5-methylphenyl]-N-(2,3-dihydroxypropyl)-2-methoxy- (9CI) (CA INDEX NAME)



L14 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1984:611126 CAPLUS
DOCUMENT NUMBER: 101:211126
TITLE: p-Oxooxazolidinylbenzene compounds as antibacterial agents
INVENTOR(S): Gregory, Walter A.
PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co. , USA
SOURCE: U.S., 21 pp. Cont.-in-part of U.S. Ser. No. 417,569, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4461773	A	19840724	US 1984-567411	19840105 <--
AU 8291032	A1	19830609	AU 1982-91032	19821201 <--
AU 560666	B2	19870416		
ES 517852	A1	19840116	ES 1982-517852	19821201 <--
ZA 8208872	A	19840725	ZA 1982-8872	19821202 <--
CA 1182824	A1	19850219	CA 1982-416882	19821202 <--
IL 67397	A1	19870331	IL 1982-67397	19821202 <--
DK 8205383	A	19830605	DK 1982-5383	19821203 <--
FI 8204182	A	19830605	FI 1982-4182	19821203 <--
FI 78078	B	19890228		
FI 78078	C	19890612		
NO 8204072	A	19830606	NO 1982-4072	19821203 <--
NO 156751	B	19870810		
NO 156751	C	19871202		
JP 58103376	A2	19830620	JP 1982-211542	19821203 <--
JP 04016471	B4	19920324		
HU 29080	O	19840130	HU 1982-3896	19821203 <--
HU 189196	B	19860630		
HU 32542	O	19840828	HU 1983-3543	19821203 <--
HU 186807	B	19850930		
SU 1194274	A3	19851123	SU 1982-3519552	19821203 <--

PRIORITY APPLN. INFO.: US 1981-327583 A2 19811204
US 1982-417569 A2 19820915
OTHER SOURCE(S): CASREACT 101:211126
GI



I

AB Phenyloxazolidinones I [R = SO2N3, SO2NHNH2, (un)substituted sulfamoyl, carbamoyl, CR2:NR3; R1 = H, alkyl, acyl, aminoacyl, carboxyacyl, HO2CCH:CHCO, 2-carboxycyclohexanecarbonyl, 2-carboxycyclohexenecarbonyl; R2 = H, alkyl, cycloalkyl; R3 = amino, OR2] were prepared **Thus**, 1-I (R = MeS, R1 = H) was dethiolated using Raney-Ni to give I (R = R1 = H) which was trifluoroacetylated and chlorosulfonylated to give 1-I (R = ClSO2, R1 = COCF3). The latter compound was treated with NH3 to give 1-I (R = H2NSO2, R1 = H), which had a min. inhibitory concentration against Escherichia coli of 29.8 μg/mL and an oral ED50 in mice against E. coli of 13.2 mg/kg.

IT **87472-05-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and debenzylation of)

RN 87472-05-7 CAPLUS

CN Benzenesulfonamide, N-(2,3-dihydroxypropyl)-4-methyl-N-phenyl- (9CI) (CA INDEX NAME)



IT **87472-23-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and ether cleavage-hydrolysis of)

RN 87472-23-9 CAPLUS

CN Benzenesulfonamide, N-[2-hydroxy-3-(phenylmethoxy)propyl]-4-methyl-N-phenyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1982:509990 CAPLUS
DOCUMENT NUMBER: 97:109990
TITLE: 3-(p-Alkylsulfonylphenyl)oxazolidinone derivatives as antibacterial agents
INVENTOR(S): Fugitt, Robert Benson; Luckenbaugh, Raymond Wilson
PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co., USA
SOURCE: Eur. Pat. Appl., 47 pp.
CODEN: EPXXDW

DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 50827	A1	19820505	EP 1981-108603	19811021 <--
EP 50827	B1	19860430		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
US 4340606	A	19820720	US 1980-199698	19801023 <--
AT 19516	E	19860515	AT 1981-108603	19811021 <--
DK 8104672	A	19820424	DK 1981-4672	19811022 <--
DK 150603	B	19870413		
DK 150603	C	19870928		
JP 57099576	A2	19820621	JP 1981-167999	19811022 <--
JP 02016303	B4	19900416		
CA 1167449	A1	19840515	CA 1981-388496	19811022 <--
AU 551485	B2	19860501	AU 1982-82257	19820401 <--
AU 8282257	A1	19831006		
HU 29158	O	19840130	HU 1982-1083	19820408 <--
HU 186856	B	19851028		
ZA 8202529	A	19831130	ZA 1982-2529	19820414 <--
IL 65534	A1	19851129	IL 1982-65534	19820419 <--
SU 1156597	A3	19850515	SU 1982-3426750	19820428 <--

PRIORITY APPLN. INFO.: US 1980-199698 A 19801023
EP 1981-108603 A 19811021

OTHER SOURCE(S): CASREACT 97:109990
GI



I

AB Oxazolidinones I (R = Me, Et, CHF2, CF3, CF2CHF2; R1 = halogen, OH, acyloxy; n = 0-2) were prepared **Thus**, 4-MeSC6H4NCO was treated with epichlorohydrin to give 62% I (R = Me, R1 = Cl, n = 0) which was oxidized to I (R = Me, R1 = Cl, n = 2). The compound had a ED50 against Staphylococcus aureus in mice of 29 mg/kg orally.

IT **82768-10-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and detosylation of)

RN 82768-10-3 CAPLUS
CN Benzenesulfonamide, N-(2,3-dihydroxypropyl)-4-methyl-N-[4-

(methylthio)phenyl]- (9CI) (CA INDEX NAME)



L14 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1981:407349 CAPLUS
DOCUMENT NUMBER: 95:7349
TITLE: Herbicidal sulfonamides, compositions containing them and their intermediates
INVENTOR(S): Adams, John Benjamin, Jr.
PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co., USA
SOURCE: Eur. Pat. Appl., 83 pp.
CODEN: EPXXDW
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 23422	A2	19810204	EP 1980-302536	19800724 <--
EP 23422	A3	19810408		
EP 23422	B1	19840222		
R: BE, DE, FR, GB, IT, LU, NL, SE				
US 4452628	A	19840605	US 1980-152021	19800530 <--
EP 64322	A2	19821110	EP 1982-200654	19800724 <--
EP 64322	A3	19821208		
EP 64322	B1	19850522		
R: BE, DE, FR, GB, IT, LU, NL, SE				

PRIORITY APPLN. INFO.: US 1979-60869 A 19790726
US 1980-152021 A 19800530
EP 1980-302536 A 19800724

GI



I

AB Sulfonylureidopyrimidines I (R = optionally substituted Ph; R1 = Me, OMe; R2 = optionally substituted alkyl, alkoxy; X = O, S; X1 = N, CH) were prepared **Thus** 4-CF3OC6H4Cl was treated with ClSO3H to give 2

isomeric sulfonyl chlorides, which were aminated, treated with COCl2, and 2-amino-4,6-dimethylpyrimidine to give I [R = 2,5-Cl(CF3O)C6H3, 5,2-Cl(CF3O)C6H3, R1 = R2 = Me, X = O, X1 = CH]. This mixture inhibited the growth of beans and cotton at 2 kg/ha post-emergence.

IT **77166-11-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with phosgene)

RN 77166-11-1 CAPLUS

CN Benzenesulfonamide, N-[2-hydroxy-3-(4-methyl-1-piperazinyl)propyl]-4-methyl-N-[2-(2-propenyloxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L14 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1975:461690 CAPLUS
DOCUMENT NUMBER: 83:61690
TITLE: Anthraquinone dyes
INVENTOR(S): Hederich, Volker; Kroeck, Friedrich W.; Gehrke, Guenter; Neeff, Ruetger
PATENT ASSIGNEE(S): Bayer A.-G., Fed. Rep. Ger.
SOURCE: Ger. Offen., 44 pp.
CODEN: GWXXBX
DOCUMENT TYPE: **Patent**
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
DE 2351517	A1	19750424	DE 1973-2351517		19731013	<--
US 3963763	A	19760615	US 1974-513485		19741009	<--
BE 820912	A1	19750410	BE 1974-149394		19741010	<--
NL 7413353	A	19750415	NL 1974-13353		19741010	<--
FR 2247510	A1	19750509	FR 1974-34361		19741011	<--
FR 2247510	B1	19781013				
JP 50067325	A2	19750606	JP 1974-116252		19741011	<--
GB 1437297	A	19760526	GB 1974-44172		19741011	<--
CH 606273	A	19781031	CH 1974-13726		19741011	<--
CH 606274	A	19781031	CH 1977-14274		19741011	<--
US 29577	E	19780314	US 1977-756707		19770104	<--
PRIORITY APPLN. INFO.:			DE 1973-2351517	A	19731013	
			US 1974-513485	A5	19741009	

GI For diagram(s), see printed CA Issue.

AB Anthraquinone dyes (I, R = NH2, OH; R1 = OH, NH2, PhNH, p-MeC6H4SO2NH, cyclohexylamino; R2 = Ph, MeC6H4, ClC6H4, H, CH2CH2OH, CH2CH2CH2OH, Cl2C6H3; R3 = MeO2C, PhO2C, EtO2C, MeSO2, p-ClC6H4SO2, PhSO2, Me2NSO2, PhNHCO; Z = CH2CH2, CH2CH2CH2, CH2CHOHCH2) were prepared and used to dye polyester, acetate, and polyamide fibers fast red shades, both from aqueous dispersions and from solvents. **Thus**, 1-amino-4-hydroxy-2-(2-anilinoethoxy)anthraquinone [55880-03-0] was dissolved in N-methylpyrrolidone at 90°, the solution cooled, and EtO2CCl [541-41-3] added in N-methylpyrrolidone to give anthraquinone dye (II) [55880-53-0]. The other 43 I were similarly prepared

IT **55880-13-2P**
RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation and polyester fiber dyeing by)

RN 55880-13-2 CAPLUS

CN Benzenesulfonamide, N-[3-[(1-amino-9,10-dihydro-4-hydroxy-9,10-dioxo-2-anthracenyl)oxy]-2-hydroxypropyl]-4-methyl-N-phenyl- (9CI) (CA INDEX NAME)



L14 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1956:89354 CAPLUS
DOCUMENT NUMBER: 50:89354
ORIGINAL REFERENCE NO.: 50:16834b-h
TITLE: N-(3-Halo-2-hydroxypropyl)-p-aminobenzoate compounds
INVENTOR(S): Weisblat, David I.; Magerlein, Barney J.; Myers, Donald R.; Hanze, Arthur R.; Rolfson, Stanley T.
PATENT ASSIGNEE(S): Upjohn Co.
DOCUMENT TYPE: **Patent**
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2737523		19560306	US	<--

AB The above compds. are intermediates in the preparation of folio acids (cf. U.S. 2,673,861, C.A. 49, 1809a) and have the generic formula p-XCH2CH(OH)CH2N(Z)C6H4CO(NHCHCO2RCH2CH2CO2R') (I). **Thus**, 248 g. 2-C10H7SO2Cl stirred slowly into a mixture of 300 mL. pyridine and 165.2 g. 4-H2NC6H4CO2Et (II), stirring continued an addnl. 30 min., the mixture cooled, 2 l. H2O added, and the precipitate filtered off and crystallized from Et
Cellosolve gave 4-(2-C10H7SO2NH)C6H4CO2Et (III), m. 188-91°. The III **thus** prepared refluxed 1 h. with 200 g. NaOH in 6 l. H2O, cooled, and acidified with HCl gave 300.4 g. 4-(2-C10H7SO2NH)C6H4CO2H (IV), m. 230-40°. IV (109 g.) stirred with 3 l. PhMe, 196 g. SO2Cl2 added during 30 min., the mixture refluxed 2 h., and the hot solution filtered deposited 101 g. 4-(2-C10H7SO2NH)C6H4COCl (V), 130-40°. A

mixture of 50 g. V, 360 mL. (ClCH2)2, and 55.7 g. di-Am glutamate H sulfate was cooled to 15°, 29.5 g. Et3N in 90 mL. (ClCH2)2 added over a 20-min. period below 20°, the mixture stirred 1.5 h., washed with 60 mL. H2O, then with 60 mL. 2N HCl, twice with saturated NaHCO3, and finally with 100 mL. saturated NaCl solution, dried, refrigerated overnight, a small amount of solid filtered off, and the (ClCH2)2 removed in vacuo. One-fourth of the residue was set aside and the remainder crystallized twice from 100 mL. alc. giving 22.5 g. of 4-(2-C10H7SO2NH)C6H4CONHCH(CO2C5H11)CH2CH2CO2Et (VI), m. 123-4.5°. Similarly was prepared 4-(p-MeC6H4SO2NH)C6H4COCl, m. 141-2°, which with di-Et L(+)-glutamate gives 4-(4-MeC6H4SO2NH)C6H4CONHCH(CO2Et)(CH2)2CO2Et (VII), m. 126°, [α]D25 -13.2° (5% MeOH + 95% EtOH). 4-(4-MeC6H4SO2NH)C6H4CO2Et and 3.4 mL. 3-chloro-1,2-epoxypropane (VIII) heated to 135°, 2 drops pyridine added, the mixture cooled after 3 min., dissolved in 50 mL. EtOH, treated 3 times with decolorizing C, and the solvent evaporated gave 4-[Z(4-MeC6H4SO2)N]C6H4CO2Et [IX, Z = ClCH2CH(OH)CH2] which was used in subsequent reactions without further purification VII (2.85 g.) and 1.1 g. VIII stirred at 135°, 2 drops of pyridine added, stirring continued 5 min. and the excess VIII removed in vacuo left 4-[Z(4-MeC6H4SO2)N]C6H4CONHCH(CO2Et)(CH2)2CO2Et (X), which was used without further purification Sufficient 10% aqueous NaOH added dropwise to a boiling EtOH solution of IX containing 3 drops phenolphthalein indicator to just maintain a pink color, and the solution diluted with water and filtered gave 4.1 g. IX (Z = 2,3-epoxypropyl), m. 71-2° (from dilute EtOH), saponified to the corresponding acid (XI), m. 124-7° (from dilute EtOH). X (1-3 g.), 20 mL. AcEt, 0.17 g. NaHCO3, and 3 mL. H2O refluxed 40 min., the solvents distilled in vacuo, the residue taken up in a mixture of Et2O and H2O containing a small proportion of alc., the Et2O layer separated, washed with cold dilute H2SO4, water, saturated NaHCO3 solution, twice with H2O, and once with saturated NaCl solution, filtered through anhydrous Na2SO4 and the ether distilled in vacuo gave 0.98 g. 4-[Z(4-MeC6H4SO2)N]C6H4CONHCH(CO2O Et)(CH2)2CO2Et (Z = allyl) as a light brown oil. A solution of 2.01 g. XI in 30 mL. 0.57N HCl in Et2O stirred 2 h. at 25° deposited crystals during the stirring; after removal of most of the Et2O in vacuo, 1.65 g. 4-[Z(4-MeC6H4SO2)N]C6H4CO2H (Z = ClCH2CH(OH)CH2), m. 157-61°, was recovered by filtering and drying.

IT **412274-66-9**, Benzoic acid, p-[N-(3-chloro-2-hydroxypropyl)-p-toluenesulfonamido]-, ethyl ester **709675-29-6**, Glutamic acid, N-[p-[N-(3-chloro-2-hydroxypropyl)-p-toluenesulfonamido]benzoyl]-, diethyl ester
(preparation of)

RN 412274-66-9 CAPLUS

CN Benzoic acid, 4-[(3-chloro-2-hydroxypropyl)[(4-methylphenyl)sulfonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 709675-29-6 CAPLUS
CN Glutamic acid, N-{p-[N-(3-chloro-2-hydroxypropyl)-p-toluenesulfonamido]benzoyl}-, diethyl ester (5CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	69.82	398.53

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-8.03	-8.76

STN INTERNATIONAL LOGOFF AT 10:29:59 ON 10 JUL 2005